Results 11 to 20 of about 14,479 (218)

Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET [PDF]

EJNMMI Research
Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific irreversible uptake may also be ...
Jessica E. Wijngaarden, Yvonne W. S. Jauw, Gerben J. C. Zwezerijnen, Berlinda J. de Wit-van der Veen, Daniëlle J. Vugts, Josée M. Zijlstra, Guus A. M. S. van Dongen, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt, Marc C. Huisman   +9 more
doaj   +2 more sources

Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications [PDF]

EJNMMI Radiopharmacy and Chemistry
Background Positron emission tomography (PET) is a highly sensitive method that provides fine resolution images, useful in the field of clinical diagnostics.
Valentina Albanese, Chiara Roccatello, Salvatore Pacifico, Remo Guerrini, Delia Preti, Silvia Gentili, Matteo Tegoni, Maurizio Remelli, Denise Bellotti, Jonathan Amico, Giancarlo Gorgoni, Emiliano Cazzola   +11 more
doaj   +2 more sources

Enhanced Tumor-to-Background Contrast with [⁵²Mn]Mn-BPPA-Bevacizumab VEGF-Targeted Immuno-PET in Cervical Cancer [PDF]

Pharmaceuticals
Background/Objectives: Radiolabeled bevacizumab-based immuno-PET tracers enable a non-invasive quantification of VEGF-A expression in gynecologic malignancies.
Csaba Csikos, Minh Toàn Ngô, Adrienn Vágner, Gábor Nagy, Gábor Ország, Tamás Nagy, Balázs Váradi, Gergő Zoltán Sajtos, István Kapus, Zoltán Szoboszlai, Dezső Szikra, Gyula Tircsó, Zoárd Tibor Krasznai, Szabolcs Molnár, Ildikó Garai, György Trencsényi   +15 more
doaj   +2 more sources

Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example [PDF]

EJNMMI Research, 2021
Background 89Zirconium-immuno-positron emission tomography (89Zr-immuno-PET) is used for assessment of target status to guide antibody-based therapy.
Marc C. Huisman, C. Willemien Menke-van der Houven van Oordt, Josée M. Zijlstra, Otto S. Hoekstra, Ronald Boellaard, Guus A. M. S. van Dongen, Dhaval K. Shah, Yvonne W. S. Jauw   +7 more
doaj   +2 more sources

Therapeutic Response Monitoring with ⁸⁹Zr-DFO-Pertuzumab in HER2-Positive and Trastuzumab-Resistant Breast Cancer Models

Pharmaceutics, 2022
Immuno-positron emission tomography (PET) has great potential to evaluate the target expression level and therapeutic response for targeted cancer therapy. Immuno-PET imaging with pertuzumab, due to specific recognition in different binding sites of HER2,
Minwoo Kang, Jong Il Shin, Sangjin Han, Jung Young Kim, Jeonghoon Park, Kwang Il Kim, Joo Hyun Kang, Tae Sup Lee   +7 more
doaj   +1 more source

Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues

Journal for ImmunoTherapy of Cancer, 2021
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types.
Gavin Thurston, Richard Tavare, Marcus P Kelly, Sosina Makonnen, Carlos Hickey, T Cody Arnold, Jason T Giurleo, Makenzie Danton, Christian Granados, Ishita Chatterjee, Drew Dudgeon, Marc W Retter, Dangshe Ma, William C Olson, Jessica R Kirshner   +14 more
doaj   +1 more source

Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma

Scientific Reports, 2021
Glypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (89Zr) and yttrium-
Kevin P. Labadie, Andrew D. Ludwig, Adrienne L. Lehnert, Donald K. Hamlin, Aimee L. Kenoyer, Kevin M. Sullivan, Sara K. Daniel, Tara N. Mihailovic, Jonathan G. Sham, Johnnie J. Orozco, Raymond S. Yeung, Delphine L. Chen, D. Scott Wilbur, Robert S. Miyaoka, James O. Park   +14 more
doaj   +1 more source

Immuno-Imaging (PET/SPECT)–Quo Vadis?

Molecules, 2022
The use of immunotherapy has revolutionized the treatment regimen of certain cancer types, but response assessment has become a difficult task with conventional methods such as CT/MRT or FDG PET-CT and the classical response criteria such as RECIST or ...
Carsten S. Kramer, Antonia Dimitrakopoulou-Strauss   +1 more
doaj   +1 more source

Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology

Frontiers in Pharmacology, 2016
Selection of the right drug for the right patient is a promising approach to increase clinical benefit of targeted therapy with monoclonal antibodies (mAbs).
Yvonne W.S. Jauw, C. Willemien Menke-van der Houwen van Oordt, Otto S. Hoekstra, N. Harry Hendrikse, Danielle J. Vugts, Josee M. Zijlstra, Marc C. Huisman, Guus A.M.S. van Dongen   +7 more
doaj   +1 more source

Role of noninvasive molecular imaging in determining response [PDF]

, 2018
The intersection of immunotherapy and radiation oncology is a rapidly evolving area of preclinical and clinical investigation. The strategy of combining radiation and immunotherapy to enhance local and systemic antitumor immune responses is intriguing ...
Marciscano, Ariel E, Thorek, Daniel L.J.
core   +2 more sources